---
search:
  boost: .9
---

# Long-acting Benzodiazepine - Xanax XR  

[Criteria Document](https://mygainwell-my.sharepoint.com/:w:/g/personal/kaelyn_dobbins_gainwelltechnologies_com/EXakDKX9EZVBhegh2Fj8TbwBFqO_D7-2EY9HGtNetYUCTg?e=nKzom7){:target="_blank" rel="noopener}

**alprazolam, extended release**

|            |                                         |
| ---------- | --------------------------------------- |
| Criteria 1 | Xanax XR (alprazolam, extended release) |

   

  

<table>
<thead>
<tr class="header">
<th><strong>Criteria Title</strong></th>
<th>Long-acting Benzodiazepine</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Criteria Subtitle</strong></td>
<td>Xanax XR (alprazolam, extended release)</td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Approval Level</strong></td>
<td>GCNSeqNo</td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><p><strong>Products</strong></p>
<table>
<thead>
<tr class="header">
<th>Preferred</th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Non-Preferred</td>
<td></td>
</tr>
<tr class="even">
<td>Brand</td>
<td></td>
</tr>
<tr class="odd">
<td>Generic</td>
<td></td>
</tr>
<tr class="even">
<td>Other</td>
<td></td>
</tr>
</tbody>
</table></td>
<td>Drug Name</td>
<td>Corresponding Code (s)</td>
<td>Type of Code (GCNSeqNo, HICL, NDC)</td>
</tr>
<tr class="even">
<td></td>
<td>XANAX XR</td>
<td>050399</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>XANAX XR</td>
<td>050400</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>XANAX XR</td>
<td>050401</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>XANAX XR</td>
<td>052143</td>
<td>GCNSeqNo</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr class="header">
<th><strong>Sequence Number</strong>  </th>
<th><strong>Question ID</strong>  </th>
<th><strong>Default Next Question ID</strong>  </th>
<th><strong>Question Type</strong>  </th>
<th><strong>Question Text</strong>  </th>
<th><strong>Choice Text</strong>  </th>
<th><strong>Next Question ID</strong>  </th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>1  </td>
<td>0998</td>
<td>  </td>
<td>Select   </td>
<td><p>Is the patient new to therapy (initial authorization request) or continuing therapy (re-authorization request)?   </p>
<p>   </p></td>
<td>New Start (initial authorization request)   </td>
<td>0999</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Continuation (re-authorization request)   </td>
<td>1234</td>
</tr>
<tr class="odd">
<td>2</td>
<td>0999</td>
<td></td>
<td>Select  </td>
<td>Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling?   </td>
<td>Y  </td>
<td>1000</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N  </td>
<td>1235  </td>
</tr>
<tr class="odd">
<td>3  </td>
<td>1000 </td>
<td>  </td>
<td>Select and Free Text</td>
<td><p>Has the patient had an inadequate clinical response to other benzodiazepines or is the patient transitioning from other benzodiazepines to alprazolam ER? </p>
<p>If yes, please submit documentation.</p></td>
<td>Y  </td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N  </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>4 </td>
<td>1234 </td>
<td> </td>
<td>Select and Free Text </td>
<td><p>Has the patient experienced clinical response with the requested medication?  </p>
<p> </p>
<p>If yes, please provide documentation.  </p></td>
<td>Y  </td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N  </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>5 </td>
<td>1235 </td>
<td> </td>
<td>Free Text </td>
<td>Please provide the rationale for the medication being requested.  </td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
</tbody>
</table>

LENGTH OF AUTHORIZATIONS: Initial authorizations will be for 180 days.
Subsequent authorizations will be for 180 days and requires
documentation of clinical response. 

 

| **Last Approved** | 4/13/2023 |
| ----------------- | --------- |
| **Other**         |           |
